IL6 and Behcet disease: Treatment with antibodies against IL-6 (BD+anti-IL-6+LT) in non-steatotic livers, and against IL-10 (BD+anti-IL-10+LT) in steatotic grafts, augmented IL-1β even more compared to those levels from its respective BD+LT group, and levels were similar in the absence or presence of steatosis, at that reperfusion time (4 h post-LT) (Figure 7B).